SAN FRANCISCO and SUZHOU, China, March 23, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic,...
Hence then, the article about innovent dosed first participant in phase 3 clinical study of ibi354 novel her2 adc for platinum resistant ovarian cancer was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for Platinum-resistant Ovarian Cancer )
Also on site :
- On Air Today: Local Musician Jesse Fox on 97.9 The Hill Presents Tabitha Meeks and Jesse Fox at Cat’s Cradle Back Room
- Could Texas Elect a Democratic Governor for the First Time in More Than 30 Years? Polls Show a Tight Race
- This Compact Sony Soundbar Is Under $100 for October Prime Day